Salim Ouertani, business unit manager at AbbVie Tunisia, has been with the affiliate since its beginning in Tunisia when it was spun-off from Abbott in 2013, being in charge of ensuring a smooth transition. Presently, AbbVie’s manager runs ethical operations and is looking forward to supporting more patients suffering from immunology diseases in Tunisia. Ouertani describes the role of AbbVie in the construction of a transparent and well-performing healthcare industry in Tunisia and supporting medical education. You were appointed as Business Unit Manager for AbbVie Tunisia in 2013 as Abbott and AbbVie separated. What were your main priorities, how did they evolve and what challenges did you face?
"In Tunisia, we strive to be pioneer in the immunology field, but most importantly we want to play an active role in the development of Tunisia’s pharmaceutical sector."